Faeth Therapeutics grants director 25K options

A Faeth Therapeutics director was granted options for 25,000 shares vesting monthly over three years.

Rhea-AI Filing Summary

Faeth Therapeutics, Inc. (FTH) reported that director Karen H. Vousden received a stock option grant for 25,000 shares of common stock on September 11, 2026. The option has an exercise price of $37.44 per share, expires on September 10, 2036, and vests in 36 equal monthly installments through September 11, 2029, contingent on her continued service. No transactions were reported under a Rule 10b5-1 trading plan.

Insider Trade Summary

Grant/Award: 25,000 shares

Grant/Award 1 txn

Insider Vousden Karen H

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	25,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 25,000 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option vest and become exercisable in 36 equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, or September 11, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

Key Figures

Option shares granted: 25,000 shares Exercise price: $37.44 per share Shares underlying option after grant: 25,000 shares +2 more

5 metrics

Option shares granted 25,000 shares Stock option award to director Karen H. Vousden on September 11, 2026

Exercise price $37.44 per share Exercise price of the stock option covering 25,000 shares

Shares underlying option after grant 25,000 shares Total option position reported following the transaction

Vesting schedule 36 monthly installments over 3 years Vesting from September 11, 2026 until fully vested on September 11, 2029

Option expiration date September 10, 2036 Final date on which the granted options may be exercised

Key Terms

Stock option, exercise price, vesting, Common Stock

4 terms

Stock option financial

"reported that Karen H. Vousden received a stock option grant for 25,000 shares"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"The option has an exercise price of $37.44 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The shares subject to the option vest and become exercisable in 36 equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Common Stock financial

"underlying security is Faeth Therapeutics Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Faeth Therapeutics (FTH) report for Karen H. Vousden?

Faeth Therapeutics reported that director Karen H. Vousden received a stock option grant for 25,000 shares of common stock on September 11, 2026, as equity compensation rather than a market purchase or sale.

What is the exercise price of the new stock options reported by FTH?

The stock options granted to Karen H. Vousden have an exercise price of $37.44 per share for Faeth Therapeutics common stock, meaning she can buy up to 25,000 shares at that price once the options vest and are exercisable.

How do the Faeth Therapeutics options granted to Karen H. Vousden vest?

The options vest and become exercisable in 36 equal monthly installments over three years, so they are fully vested on September 11, 2029, provided Karen H. Vousden continues serving the company on each vesting date.

When do Karen H. Vousden’s Faeth Therapeutics options expire?

The options granted to Karen H. Vousden expire on September 10, 2036. After that date, any unexercised portion of the 25,000-share stock option will no longer be exercisable.

Were the FTH insider options granted under a Rule 10b5-1 trading plan?

No. The filing indicates that the transactions were not made under a Rule 10b5-1 trading plan, meaning they were not executed pursuant to a pre-arranged trading program under that rule.

How many Faeth Therapeutics shares does this new option cover in total?

The newly granted stock option to Karen H. Vousden covers 25,000 shares of Faeth Therapeutics common stock. After this grant, her reported holdings of this option series are 25,000 option shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 04:59 PM Accepted by SEC EDGAR 09/15/2026 - 04:58 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vousden Karen H

(Last) (First) (Middle)

C/O FAETH THERAPEUTICS, INC.

701 TILLERY STREET #12 #1010

(Street)

AUSTIN TEXAS 78702

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Faeth Therapeutics, Inc. [ FTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$37.44	09/11/2026		A		25,000		(1)	09/10/2036	Common Stock	25,000	$0	25,000	D

Explanation of Responses:

1. The shares subject to the option vest and become exercisable in 36 equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, or September 11, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

	/s/ Josiah Craver, Attorney-in-Fact	09/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)